Acuta Capital Partners, LLC Arcellx, Inc. Transaction History
Acuta Capital Partners, LLC
- $70.3 Million
- Q4 2024
A detailed history of Acuta Capital Partners, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 10,743 shares of ACLX stock, worth $696,361. This represents 1.16% of its overall portfolio holdings.
Number of Shares
10,743
Previous 62,100
82.7%
Holding current value
$696,361
Previous $5.19 Million
84.22%
% of portfolio
1.16%
Previous 5.25%
Shares
5 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$283 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$243 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$228 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$226 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$216 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.84B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...